ANALGESIC AND MUSCLE RELAXANT CAPLETS TABLET
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
09-01-2013
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
IBUPROFEN; METHOCARBAMOL
Tilgængelig fra:
TEVA CANADA LIMITED
ATC-kode:
M03BA53
INN (International Name):
METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS
Dosering:
200MG; 500MG
Lægemiddelform:
TABLET
Sammensætning:
IBUPROFEN 200MG; METHOCARBAMOL 500MG
Indgivelsesvej:
ORAL
Enheder i pakken:
18/40
Recept type:
OTC
Terapeutisk område:
CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS
Produkt oversigt:
Active ingredient group (AIG) number: 0248961001; AHFS:
Autorisation status:
CANCELLED POST MARKET
Autorisation dato:
2021-08-12
Produktets egenskaber
1 | P a g e
PRODUCT MONOGRAPH
ANALGESIC & MUSCLE RELAXANT CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED
Date of Preparation:
30 Novopharm Court
January 8, 2013
Toronto, Canada
M1B 2K9
Control# 161025
2 | P a g e
TABLE OF CONTENTS
Clinical Pharmacology
..............................................................................................................................
3
Indications:
................................................................................................................................................
7
Contraindications
......................................................................................................................................
8
Warnings:
..................................................................................................................................................
8
Precautions
..............................................................................................................................................
12
Drug Interactions
....................................................................................................................................
13
Adverse Reactions
..................................................................................................................................
15
Symptoms and Treatment of Overdose
...................................................................................................
17
Dosage and
Administration.....................................................................................................................
18
Pharmaceutical Information
....................................................................................................................
19
Composition:
...........................................................................................................................................
21
Availability of Dosage Forms
..........................
Læs hele dokumentet
